Iterum Therapeutics plc (ITRMF) Change in Account Payables (2017 - 2025)

Iterum Therapeutics has reported Change in Account Payables for 9 years, with the latest figure at -$612000.0 in Q3 2025.

• On a quarterly basis, Change in Account Payables fell 4471.43% year-over-year to -$612000.0 in Q3 2025; TTM through Sep 2025 was -$258000.0, a 94.49% increase from a year earlier, with the FY2024 full-year figure at -$4.7 million, down 313.45% from the prior year.
• Change in Account Payables was -$612000.0 for Q3 2025 at Iterum Therapeutics, down from $777000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $1.8 million in Q3 2023, with the low at -$2.1 million in Q2 2024.
• Average Change in Account Payables over 5 years is -$12526.3, with a median of $92000.0 recorded in 2021.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables surged 1337.86% in 2023, then plunged 4471.43% in 2025.
• Over 5 years, Change in Account Payables stood at $603000.0 in 2021, then soared by 156.05% to $1.5 million in 2022, then sank by 133.55% to -$518000.0 in 2023, then dropped by 12.74% to -$584000.0 in 2024, then retreated by 4.79% to -$612000.0 in 2025.
• The last three Change in Account Payables figures came in at -$612000.0 (Q3 2025), $777000.0 (Q2 2025), and $161000.0 (Q1 2025), per Business Quant data.